| Title | Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer |
| Authors | Zhang, Yuanyuan Chen, Hongyan Mo, Hongnan Hu, Xueda Gao, Ranran Zhao, Yahui Liu, Baolin Niu, Lijuan Sun, Xiaoying Yu, Xiao Wang, Yong Chang, Qing Gong, Tongyang Guan, Xiuwen Hu, Ting Qian, Tianyi Xu, Binghe Ma, Fei Zhang, Zemin Liu, Zhihua |
| Affiliation | Peking Univ, Acad Adv Interdisciplinary Studies, Sch Life Sci, Int Canc Inst,BIOPIC,Peking Tsinghua Ctr Life Sci, Beijing 100871, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China Chinese Acad Med Sci & Peking Union Med Coll, Dept Ultrasound, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China Canc Hosp HuanXing ChaoYang Dist, Dept Med Oncol, Beijing 100005, Peoples R China Shenzhen Bay Lab, Inst Canc Res, Shenzhen 518132, Peoples R China |
| Keywords | B-CELLS T-CELLS TUMOR LANDSCAPE IMMUNOTHERAPY CHALLENGES OPPORTUNITIES MECHANISMS GENERATION SURVIVAL |
| Issue Date | 13-Dec-2021 |
| Publisher | CANCER CELL |
| Abstract | In triple-negative breast cancer (TNBC), the benefit of combining chemotherapy with checkpoint inhibitors is still not very clear. We utilize single-cell RNA- and ATAC-sequencing to examine the immune cell dynamics in 22 patients with advanced TNBC treated with paclitaxel or its combination with the anti-PD-L1 atezolizumab. We demonstrate that high levels of baseline CXCL13(+) T cells are linked to the proinflammatory features of macrophages and can predict effective responses to the combination therapy. In responsive patients, lymphoid tissue inducer (LTi) cells, follicular B (Bfoc) cells, CXCL13(+) T cells, and conventional type 1 dendritic cells (cDC1) concertedly increase following the combination therapy, but instead decrease after paclitaxel monotherapy. Our data highlight the importance of CXCL13(+) T cells in effective responses to anti-PD-L1 therapies and suggest that their reduction by paclitaxel regimen may compromise the clinical outcomes of accompanying atezolizumab for TNBC treatment. |
| URI | http://hdl.handle.net/20.500.11897/632799 |
| ISSN | 1535-6108 |
| DOI | 10.1016/j.ccell.2021.09.010 |
| Indexed | SCI(E) |
| Appears in Collections: | 前沿交叉学科研究院 |
